Table 7 Clinicopathologic characteristics in VNPI intermediate scores according to treatment (TM; total mastectomy in intermediate VNPI score)

Age (yr)

49.1±9.5

48.1±7.9

48.7±9.5

.979

  ≤40

2(14.3%)

7(11.7%)

6(14.0%)

  41-60

11(78.6%)

50(82.0%)

33(76.7%)

  ≥61

1(7.1%)

4(6.6%)

4(9.3%)

Microcalcification

.983

  Yes

9(64.3%)

38(62.3%)

28(65.1%)

  No

5(35.7%)

23(37.7%)

15(34.9%)

Multifocality

.314

  Yes

1(7.1%)

9(14.8%)

10(23.3%)

  No

13(92.9%)

52(85.2%)

33(76.7%)

Tumor size (mm)

13.93±12.07

29.90±18.11

50.74±23.49

.001

  ≤15

11(78.6%)

14(23.0%)

1(2.3%)

  16-40

2(14.3%)

30(49.2%)

15(34.9%)

  ≥41

1(7.1%)

17(27.9%)

27(62.8%)

Tumor grade

.360

  1

2(14.3%)

8(13.1%)

1(2.3%)

  2

7(50.0%)

36(59.0%)

28(65.1%)

  3

5(35.7%)

17(27.9%)

14(32.6%)

Margin (mm)

8.93±7.97

7.80±7.58

.221

  >9

5(35.7%)

18(29.5%)

-

  1-9

9(64.3%)

32(52.5%)

-

  <1

0

11(18.0%)

-

VNPI score

7.5±0.7

8.2±0.8

8.0±0.9

.021

Receptor status

 ER positive

13(92.9%)

40(65.6%)

28(65.1%)

.110

 PR positive

10(71.4%)

38(62.3%)

21(48.8%)

.240

C-erbB2

.636

  0

3(21.4%)

6(9.8%)

6(14.0%)

  1+

2(14.3%)

10(16.4%)

11(25.6%)

  2+

3(21.4%)

18(29.5%)

6(14.0%)

  3+

6(42.9%)

26(42.6%)

18(41.9%)

  Unknown

0

1(1.7%)

2(4.7%)

Ki67 status (%)

12.8±12.39

13.65±15.54

12.91±15.94

.847

Tamoxifen

12(85.7%)

43(68.9%)

30(69.8%)

.467

Recurrence

0

5(8.3%)

0

.418